EyeControl Overview
EyeControl is a medical technology company revolutionizing ICU care with its AI-powered eye-tracking platform. Designed to empower mechanically ventilated patients, it enables effective communication, connects families and caregivers, and provides healthcare teams with actionable insights. By supporting implementation of evidence-based practices for optimizing critical care, EyeControl enhances patient safety, improves cognitive and mental health outcomes, and fosters meaningful connections. The EyeControl device is FDA-listed, CE-marked, ISO-certified, and AMAR and MAKAT registered as a communication solution. It is federally reimbursed in Israel for inpatient settings and homecare.
Cumulative Funding Raised Over Time ($)
$50KAug 2015
$7.5MAug 2020
$7.5MOct 2017
$8.5MSep 2023
Latest News
growth-positive
Israeli company EyeControl creates revolutionary medical technology
EyeControl, an Israeli company, has developed a revolutionary medical technology that allows ICU patients to communicate through eye gestures and a bone conduction headset. This technology is proving beneficial in preventing cognitive decline and enhancing patient experiences, particularly for soldiers. The company is conducting clinical trials in Israel and the US, supported by the Israel-US Binational Industrial Research and Development fund and the NIH AI program. Recent investments from the European Bank and Googles AI Fund are aiding its expansion. EyeControls technology is being implemented in hospitals under Clalit in Israel and selected sites in the US. The company aims to reduce ICU delirium and improve patient care globally.
InvestmentPartners
growth-positive
Talking to the unconscious: Israelis reduce delirium during surgery
EyeControl, a startup founded in 2016, has developed a device that aids communication for ICU patients who are unable to speak due to sedation or injury. The device, which uses eye-tracking technology, allows patients to communicate through pre-prepared messages. It has shown promise in reducing ICU delirium and is currently being tested in a large trial involving hospitals like Assuta Ashdod and Beilinson Hospital. The trial is partially funded by the BIRD Fund and NIH, with a budget of $1.8 million. EyeControls technology is seen as a potential game-changer in ICU care, offering both clinical and economic benefits. The company has raised about $10 million and received $8 million in grants, positioning itself for growth in the hospital market.
InvestmentPartners
Growth-Positive
הסטארט-אפ הזה מצא שיטה מפתיעה להפחית הזיות בטיפול נמרץ
Israeli start-up EyeControl has developed a device that allows medical teams and families to communicate with sedated patients, reducing delirium and simultaneously serving as a means for patients to communicate with their eyes. The device, which came into existence in 2016, has become increasingly necessary in intensive care units. Dr. Ami Mayo, director of intensive care at the public hospital Asuta Ashdod, admitted he was surprised when a patient who woke up and became agitated in his department immediately calmed down when the companys device was put on him.
Customers
Israeli med tech company’s innovative headset could reduce delirium in ICU patients
growth-positive
EyeControl פיתחה אביזר אלחוטי המאפשר למונשמים וחולי ALS לתקשר - Techtime - חדשות אלקטרוניקה והייטק
Israeli start-up EyeControl has developed a wireless wearable device that enables patients who struggle to speak due to their medical condition to communicate using only eye movements. The device was originally developed for patients with ALS who have lost their ability to speak. The company has also developed a version for hospital patients, EyeControl-Med. The company is currently completing a clinical study to demonstrate how their communication device can help reduce delirium among hospitalized patients. Preliminary findings from the study suggest that the device reduced the number of errors made by patients in delirium tests and improved communication and interaction with the hospital staff.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $15.21M |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 13 |
| Investors | 13 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.eyecontrol.co.il |
Locations
Menachem Begin Street 48, Tel Aviv, Israel
Photos & Videos
6 item(s)
EyeControl Business
Business models
B2C, B2B, B2B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesAssistive DevicesDigital HealthcareDigital Accessibility SolutionsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
Platforms & InterfacesSoftwareMobileSemiconductors & ElectronicsWearablesArtificial IntelligenceMachine LearningComputer VisionCommunicationsTags (26)
mental-healthhome-caredegenerative-diseasesneurologymhealthcomputer-visiondigital-healthcaremobile-applicationspatientseye-trackinghospitalsamyotrophic-lateral-sclerosis-(als)artificial-intelligencenon-invasivewearabledisabilitiesassistive-devicesventilationmultiple-sclerosiswireless-communicationstrokemedical-devicesmachine-learningmedical-technologiescommunicationsnatural-language-processingGeographic Markets
IsraelUnited StatesEyeControl Financials
$15.21M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
A
Funding stage
13
Total rounds
13
Investors
Cumulative Funding Raised Over Time ($)
$50KAug 2015
$7.5MAug 2020
$7.5MOct 2017
$8.5MSep 2023
Private Equity Funding
Undisclosed Round
Sep 2023
$908K
European Innovation Council
A Round
Aug 2020
$7.5M
Connecticut Innovations (Lead)
,
Clive Barret, Itsik Danizger, Menomadin Foundation, Impact First Investments, Benslie International Ltd, Benny Levin, Jim Elkind, Rimonci Capital, ZORA Ventures, Avi Kornreich
Seed
Oct 2017
Undisclosed
ZORA Ventures
Crowdfunding
Aug 2015
$50K
Indiegogo
Non-Equity Funding
GrantEvent
May 2024
Undisclosed
Google AI Startup Fund
GrantEvent
Jan 2024
Undisclosed
a2 collective
GrantEvent
Jan 2023
Undisclosed
BIRD Foundation (Lead)
GrantEvent
Jan 2022
$900K
BIRD Foundation
GrantEvent
Aug 2020
$2.5M
EU Horizon 2020
GrantEvent
Oct 2019
$750K
VentureClash
GrantEvent
Nov 2017
$2M
European Commission
GrantEvent
Jul 2016
$650K
Office of the Chief Scientist
GrantEvent
Jul 2016
$5K
Cydan
EyeControl Lifecycle
Cumulative Funding Raised Over Time
$50KAug 2015
$7.5MAug 2020
$7.5MOct 2017
$8.5MSep 2023
All Events
Undisclosed Round
Sep 2023
$908K
European Innovation Council
A Round
Aug 2020
$7.5M
Connecticut Innovations (Lead)
,
Clive Barret, Itsik Danizger, Menomadin Foundation, Impact First Investments, Benslie International Ltd, Benny Levin, Jim Elkind, Rimonci Capital, ZORA Ventures, Avi Kornreich
Seed
Oct 2017
Undisclosed
ZORA Ventures
Crowdfunding
Aug 2015
$50K
Indiegogo
GrantEvent
May 2024
Undisclosed
Google AI Startup Fund
GrantEvent
Jan 2024
Undisclosed
a2 collective
GrantEvent
Jan 2023
Undisclosed
BIRD Foundation (Lead)
GrantEvent
Jan 2022
$900K
BIRD Foundation
GrantEvent
Aug 2020
$2.5M
EU Horizon 2020
GrantEvent
Oct 2019
$750K
VentureClash
GrantEvent
Nov 2017
$2M
European Commission
GrantEvent
Jul 2016
$650K
Office of the Chief Scientist
GrantEvent
Jul 2016
$5K
Cydan
EyeControl News
10 articles
growth-positive
Israeli company EyeControl creates revolutionary medical technology
EyeControl, an Israeli company, has developed a revolutionary medical technology that allows ICU patients to communicate through eye gestures and a bone conduction headset. This technology is proving beneficial in preventing cognitive decline and enhancing patient experiences, particularly for soldiers. The company is conducting clinical trials in Israel and the US, supported by the Israel-US Binational Industrial Research and Development fund and the NIH AI program. Recent investments from the European Bank and Googles AI Fund are aiding its expansion. EyeControls technology is being implemented in hospitals under Clalit in Israel and selected sites in the US. The company aims to reduce ICU delirium and improve patient care globally.
InvestmentPartners
growth-positive
Talking to the unconscious: Israelis reduce delirium during surgery
EyeControl, a startup founded in 2016, has developed a device that aids communication for ICU patients who are unable to speak due to sedation or injury. The device, which uses eye-tracking technology, allows patients to communicate through pre-prepared messages. It has shown promise in reducing ICU delirium and is currently being tested in a large trial involving hospitals like Assuta Ashdod and Beilinson Hospital. The trial is partially funded by the BIRD Fund and NIH, with a budget of $1.8 million. EyeControls technology is seen as a potential game-changer in ICU care, offering both clinical and economic benefits. The company has raised about $10 million and received $8 million in grants, positioning itself for growth in the hospital market.
InvestmentPartners
Growth-Positive
הסטארט-אפ הזה מצא שיטה מפתיעה להפחית הזיות בטיפול נמרץ
Israeli start-up EyeControl has developed a device that allows medical teams and families to communicate with sedated patients, reducing delirium and simultaneously serving as a means for patients to communicate with their eyes. The device, which came into existence in 2016, has become increasingly necessary in intensive care units. Dr. Ami Mayo, director of intensive care at the public hospital Asuta Ashdod, admitted he was surprised when a patient who woke up and became agitated in his department immediately calmed down when the companys device was put on him.
Customers
Israeli med tech company’s innovative headset could reduce delirium in ICU patients
growth-positive
EyeControl פיתחה אביזר אלחוטי המאפשר למונשמים וחולי ALS לתקשר - Techtime - חדשות אלקטרוניקה והייטק
Israeli start-up EyeControl has developed a wireless wearable device that enables patients who struggle to speak due to their medical condition to communicate using only eye movements. The device was originally developed for patients with ALS who have lost their ability to speak. The company has also developed a version for hospital patients, EyeControl-Med. The company is currently completing a clinical study to demonstrate how their communication device can help reduce delirium among hospitalized patients. Preliminary findings from the study suggest that the device reduced the number of errors made by patients in delirium tests and improved communication and interaction with the hospital staff.
InvestmentExpand
growth-positive
EyeControl Expands R&D Program with EyeControl-Pro for Delirium
EyeControl is developing an AI-based, wearable eye-tracking communication solution called EyeControl-Pro for Delirium reduction. The company will display its new device at the American Delirium Society Conference in Indianapolis. EyeControl-Pro is designed to enable bi-directional remote connectivity and communication between the patients headset, the medical team, and family members. The company will also share early data from its phase I clinical trial in Israel at Beilinson Hospitals ICU. The device is currently being evaluated in a multi-center, international clinical trial for its safety and efficacy in reducing Delirium.
InvestmentCustomers
growth-positive
Patients communication co EyeControl raises $10m
Israeli startup EyeControl has closed a Series A round of funding and won the Enhanced European Innovation Council’s (EIC) Covid-19 Pilot Program, securing over $10 million in combined funding. The funding will allow the company to expand its hospital activity and enhance strategic partnerships. EyeControl is piloting its medical device at hospitals treating Covid-19 patients to preserve communication between ventilated patients and nurse stations. Avner Halperin has been appointed as Chairman of the companys Board of Directors. EyeControl was founded by CEO Or Retzkin and CTO Itai Kornberg.
InvestmentPartners
growth-positive
EyeControl headset for locked-in patients available on NHS Supply Chain
EyeControl, a wearable device that enables patients with locked-in syndrome to communicate through eye movements, is now available on the NHS Supply Chain Framework. The device, which includes an eye-tracking camera and audio speaker, allows individuals with limited mobility to communicate with their loved ones and carers. It works without the need for a large screen and can be worn at all times, providing immediate communication 24 hours a day. The device has been tested by speech therapists and has received positive feedback. EyeControl aims to provide a voice to locked-in individuals and is excited to deliver the first devices to patients in the UK.
Customers
growth-positive
EyeControl wearable aims to give voice to locked-in patients in UK
Israeli healthtech firm EyeFree Assisting Technology has launched a crowdfunding campaign to bring its eye-controlled wearable device, EyeControl, to the UK. EyeControl is designed for patients with locked-in syndrome, allowing them to communicate through eye movements. The device consists of a head-mounted infrared camera that tracks eye movements and translates them into audio communication. EyeControls crowdfunding campaign aims to sponsor devices for individuals with motor neurone disease in the UK. The company has pledged to fund-match money raised by the public to provide as many devices as possible free of charge to patients.
Customers
growth-positive
Novel Eye-Tracking Device EyeControl Enables ALS Patients To Communicate
EyeControl, an Israeli-made device, is aiming to give a voice to those who are unable to verbally communicate due to ALS. The device uses eye movements to capture audio or text commands, allowing patients to call for assistance, put together pre-determined sentences, and compose sentences by swiping their eyes. EyeControl has launched an Indiegogo crowdfunding campaign to raise $30,000, which has already exceeded its goal and reached $42,000. The company has extended the campaign to raise up to $50,000. EyeControl has partnered with the non-profit organization Prize4Life to raise awareness for ALS and advocate for its solution. Unlike other eye-gaze systems, EyeControl is portable and affordable, with a price expected to be $100.
Customers
EyeControl Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 22 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 18 classification IDs that could be used for matching.
EyeControl Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 101/100 |
| Missing | markets |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515381028 |
| Crunchbase | eyecontrol |
| Creator | Alyssa Williams |
| Creator email | williamsar95@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-10-31T00:00:00.000Z |
| Created | 2015-07-13T00:00:00.000Z |
| Claimed | Yes |